

Minimal Information About T Cell Assays (MIATA)

 consortiapedia.fastercures.org/consortia/miata/

Research Areas



Tool Development

Regulatory



Basic Research



Product Development

Device

At a Glance

- Status: **Active Consortium**
- Year Launched: **2009**
- Initiating Organization: **Individual Participants**
- Initiator Type: **Academia**
- Location: **International**

Abstract

(Minimal Information About T cell Assays) MIATA summarizes in 5 modules the essential information to be included in the Materials and Methods section of publications to provide the transparency sought by peers and reviewers, as defined in a 3 year public consultation process. The MIATA website provides the information about how to easily implement MIATA, including I) the MIATA guidelines, II) a checklist that can be executed online, III) example reports, IV) pre-established editable materials and method documents with fill-in options to assist in MIATA-compliant reporting, and V) tools assisting with donor information and term definition. MIATA-compliant papers are listed in the MIATA “Hall of Fame” with links to the original article, providing enhanced visibility of the published work.

Mission

The mission of MIATA is to provide a standard for publications about T cell assays so that peers and reviewers can easily discern the methods used to obtain the information. This will allow the scientific community to more easily vet such publications, while encouraging advancements in the field through clear communication.

Structure & Governance

The MIATA project is led by the MIATA core team, a core group of immunologists who initiated it.

Impact/Accomplishment

For information on MIATA's progress, click [here](#)

Links/Social Media Feed

Homepage <http://miataproject.org/>

Points of Contact

sylvia@zellnet.com
cedrik.britten@ribological.de

Sponsors & Partners

JPT Innovative Peptide Solutions

Mabtech

The Immunoguiding Program (CIP) of the Association of Immunotherapy of Cancer (CIMT)

The Immunassay and Flow Cytometry Shared Resource (Dartlab) of Dartmouth Medical School

The Human Immune Monitoring Center (HIMC) of Stanford University

The Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI)

Zellnet Consulting, Inc.

The Network Italiano per la Bloterapia dei Tumori (NIBIT)

Updated: **06/21/2017**